<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14997">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01956708</url>
  </required_header>
  <id_info>
    <org_study_id>RIPC-13-5507-BO</org_study_id>
    <nct_id>NCT01956708</nct_id>
  </id_info>
  <brief_title>Transfer of Cardioprotection During RIPC</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Remote ischemic preconditioning (RIPC) with transient upper limb ischemia/reperfusion
      provides peri-operative myocardial protection, is safe and improves prognosis in patients
      undergoing elective CABG surgery.

      The signal transfer from limb to heart is unknown. Thus, the aim of this study is to
      identify the pathways which transfer the cardioprotective signal from the
      ischemic/reperfused extremity to the heart in humans undergoing surgical coronary
      revascularization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will obtain arterial blood samples before skin incision and 1-72 h after
      the remote ischemic preconditioning protocol and analyze them biochemically. The
      investigators focus on those ligands that have been previously implicated in conditioning
      protocols at any organ. In addition, the investigators will use a bioassay system,
      consisting of a Langendorff-perfused isolated heart with coronary occlusion/reperfusion and
      infarct size by TTC staining as endpoint, and then expose this bioassay system to arterial
      plasma obtained after the remote ischemic preconditioning stimulus or placebo. This approach
      will allow us to further characterize any potential transfer signal candidate with a
      pharmacological antagonist approach.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Myocardial protection: cumulative postoperative troponin I release</measure>
    <time_frame>72 h, postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days and 1 year after CABG surgery and after complete follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebrovascular events (MACCE)</measure>
    <time_frame>30 days and 1 year after CABG surgery  after complete follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function (creatinine and eGFR)</measure>
    <time_frame>72 h, postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardioprotective factors released into circulating blood</measure>
    <time_frame>before skin incision versus 1-72 h after RIPC</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">332</enrollment>
  <condition>CABG</condition>
  <arm_group>
    <arm_group_label>RIPC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):
after induction of anesthesia and before surgery: 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200mmHg and 5 minutes of reperfusion Anesthesia is with isoflurane (0.7-0.8% end-tidal) +sufentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):
after induction of anesthesia and before surgery: the cuff is left uninflated</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RIPC</intervention_name>
    <description>3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion</description>
    <arm_group_label>RIPC</arm_group_label>
    <other_name>RIPC: Remote ischemic preconditioning</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive patients &gt; 18 years after written informed consent

          -  elective, isolated CABG surgery with and without valvuloplastic surgery

          -  two-stage cannulation, cardiopulmonary bypass

          -  antegrade Bretschneider cardioplegia

          -  mild hypothermia (32°C)

          -  preoperative standard medication (statins, betablocker, aspirin)

          -  standard anesthesia (see above)

          -  intraoperative standard protocol (full heparinization with ACT, aprotinin, protamin)

          -  postoperative standard protocol (500 mg aspirin after 2 h, low-dose heparin after 4
             h)

        Exclusion Criteria:

        preoperative

          -  prior percutaneous coronary intervention (PCI) within 6 weeks

          -  any preoperative troponin I elevation

          -  renal insufficiency (creatinine &gt;200 µmol/l)

          -  reoperation

          -  emergency surgery

          -  acute coronary syndrome (unstable angina, STEMI, NSTEMI) within 4 weeks

          -  dual anti-platelet therapy (clopidogrel+aspirin)

        intraoperative

          -  harvesting of a. radialis

          -  coronary thrombendarterectomy

          -  complications (bypass-low flow/ -occlusion)

          -  antithrombotic therapy (intraoperative clopidogrel + aspirin)

          -  retrograde cardioplegia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Kamler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Essen - Huttrop gGmbH, Einrichtung des Universitätsklinikums Essen,  Essen, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Kamler, MD</last_name>
    <phone>+49-201-2802211</phone>
    <email>markus.kamler@uk-essen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Petra Kleinbongard, PhD</last_name>
    <phone>+49-201-723-2763</phone>
    <email>petra.kleinbongard@uk-essen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herzzentrum Essen - Huttrop gGmbH, Einrichtung des Universitätsklinikums Essen</name>
      <address>
        <city>Essen</city>
        <zip>4130</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Kamler, MD</last_name>
      <phone>+49-201-2802211</phone>
      <email>markus.kamler@heh.uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Petra Kleinbongard, PhD</last_name>
      <phone>+49-201-723-2763</phone>
      <email>petra.kleinbongard@uk-essen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Markus Kamler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 7, 2013</lastchanged_date>
  <firstreceived_date>September 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Markus Kamler</investigator_full_name>
    <investigator_title>Prof. Dr. med. Markus Kamler</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
